Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GYRE THERAPEUTICS, INC.CBIO · Entity 5247 | Chief Scientific Officer | August 09, 2022 | August 10, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GYRE THERAPEUTICS, INC.
Report date August 09, 2022 · Filed August 10, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,417 |
Reported balance
After 2022-08-09 transaction · row 1
1 source rowRow 1 · 2022-08-09 · Purchase · Acquired 3,250 · Balance 9,417 F1: Shares purchased under the Issuer's 2018 Employee Stock Purchase Plan on August 9, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares purchased under the Issuer's 2018 Employee Stock Purchase Plan on August 9, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 09, 2022 Filed Aug 10, 2022 21:17 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | PurchaseCommon Stock | 3,250 | $0.47 | $1,527.50 |
DisclosureSEC source: 0001209191-22-045251 · doc4.xml · nonDerivative · entry 1 Blouse Grant E. · CIK 0001869883 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,417 F1 · shares: Shares purchased under the Issuer's 2018 Employee Stock Purchase Plan on August 9, 2022. Read SEC document |
| February 11, 2022 Filed Feb 23, 2022 21:05 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0001209191-22-012156 · doc4.xml · derivative · entry 1 Blouse Grant E. · CIK 0001869883 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2032-02-11 F1 · derivative.exercise_date: 1/4 of the shares subject to the option will vest on the one-year anniversary of the vesting commencement date of February 11, 2022, and 1/48 of the shares subject to the option will vest on each monthly anniversary of the vesting commencement date thereafter. Read SEC document |
| February 09, 2022 Filed Feb 17, 2022 01:07 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | PurchaseCommon Stock | 3,250 | $0.46 | $1,495.00 |
DisclosureSEC source: 0001209191-22-010392 · doc4.xml · nonDerivative · entry 1 Blouse Grant E. · CIK 0001869883 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,167 F1 · shares: Shares purchased under the Issuer's 2018 Employee Stock Purchase Plan on February 9, 2022. Read SEC document |
| August 09, 2021 Filed Aug 11, 2021 13:13 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | PurchaseCommon Stock | 1,163 | $3.62 | $4,210.06 |
DisclosureSEC source: 0001209191-21-050757 · doc4.xml · nonDerivative · entry 1 Blouse Grant E. · CIK 0001869883 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,917 F1 · shares: Shares purchased under the Issuer's 2018 Employee Stock Purchase Plan on August 9, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.